PharmacoEconomics

, Volume 9, Issue 2, pp 113–120 | Cite as

The Decision Rules of Cost-Effectiveness Analysis

  • Göran Karlsson
  • Magnus Johannesson
Leading Article

Summary

It has become increasingly popular to carry out cost-effectiveness analyses in economic evaluations of healthcare programmes. Cost-effectiveness analysis is based on the maximisation of the health effects for a given amount of resources. However, many published studies fail to report the results of cost-effectiveness analysis in a way that is consistent with this underlying aim. The aim of this article is to demonstrate the decision rules of cost-effectiveness analysis in an easily accessible way for practitioners in the field. A hypothetical example is used to demonstrate the decision rules of cost-effectiveness analysis, and we also show how to estimate the appropriate incremental cost-effectiveness ratios and how to exclude dominated alternatives. It is then shown how fixed budgets or predetermined prices per effectiveness unit can be used as decision rules to maximise health effects and to determine which programmes to implement on the basis of incremental cost-effectiveness ratios. We hope that the article will contribute towards an increased understanding and application of the appropriate decision rules of cost-effectiveness analysis, so that the results of cost-effectiveness analyses can be interpreted meaningfully by decision makers.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Weinstein MC, Zeckhauser R. Critical ratios and efficient allocation. J Public Econ 1973; 2: 147–57CrossRefGoogle Scholar
  2. 2.
    Weinstein M. Principles of cost-effective resource allocation in health care organisations. Int J Technol Assess Health Care 1990; 6: 93–105PubMedCrossRefGoogle Scholar
  3. 3.
    Karlsson G. Economic evaluation of dental implants [in Swedish]. Linköping Studies in Arts and Science 69. Linköping: Linköping University, 1991Google Scholar
  4. 4.
    Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. J Health Econ 1993; 12: 459–67PubMedCrossRefGoogle Scholar
  5. 5.
    Sintonen H, Alander V. Comparing the cost-effectiveness of drug regimens in the treatment of duodenal ulcers. J Health Econ 1990; 9: 95–101CrossRefGoogle Scholar
  6. 6.
    Buxton MJ, O’Brien BJ. Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting. Br J Cancer 1992; 66 Suppl.: S64–7Google Scholar
  7. 7.
    Garattini L, Grilli R, Scopelliti D, et al. A proposal for Italian guidelines in pharmacoeconomics. PharmacoEconomics 1995; 7: 1–6PubMedCrossRefGoogle Scholar
  8. 8.
    Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertens 1991; 9: 199–208PubMedCrossRefGoogle Scholar
  9. 9.
    Johannesson M. The relationship between cost-effectiveness analysis and cost-benefit analysis. Soc Sci Med 1995; 41: 483–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Göran Karlsson
    • 1
  • Magnus Johannesson
    • 1
  1. 1.Centre for Health EconomicsStockholm School of EconomicsStockholmSweden

Personalised recommendations